Building a New Kind of Biopharma Company
We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.
Our Story
Our Values
Leading with Courage
Courage
Quickly solving challenging issues
Compassion
Putting patients first to dramatically transform their lives
Collaboration
Building strong, innovative and diverse teams focused on developing therapeutics through efficient win/win partnerships
Innovation
A different kind of biopharma redefining what is possible
A Sense of Urgency
Accelerating development and commercialization of transformative medicines for serious diseases
Meet Our Leadership
We are led by experienced biopharma executives with exceptional track records of building strong, innovative and diverse teams across the healthcare industry.
Meet Our Leadership
See Our Pipeline
We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients.
See Our PipelineOur Advantage
Building a Different Kind of Biopharma Company
We have the right blend of experience along with a broad network of relationships across healthcare to acquire, develop and commercialize the most promising therapeutic programs to transform patients’ lives.
Search and Select the Best
We leverage the global network of our team and investors to identify promising assets using their cumulative development and commercial expertise.
Efficiently Build the Portfolio
We utilize our deep experience in business development to identify win-win licenses, partnerships, or acquisitions that enable rapid creation of ACELYRIN’s therapeutics portfolio.
Maximize Program Potential
We design and implement development programs aiming to reduce risks and accelerate timelines while maximizing the therapeutic and commercial potential.
Rapidly Assemble Teams and Resources
We can rapidly assemble teams and resources required for efficient execution of the development, regulatory, manufacturing, and commercial processes.
Latest Press Releases
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
Press Release
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
Read more 